[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Axogen Inc (AXGN)

Axogen Inc (AXGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,176,576
  • Shares Outstanding, K 53,178
  • Annual Sales, $ 225,210 K
  • Annual Income, $ -15,700 K
  • EBIT $ -9 M
  • EBITDA $ 0 M
  • 60-Month Beta 1.17
  • Price/Sales 9.63
  • Price/Cash Flow N/A
  • Price/Book 8.86

Options Overview Details

View History
  • Implied Volatility 56.69% (+3.99%)
  • Historical Volatility 57.19%
  • IV Percentile 6%
  • IV Rank 6.79%
  • IV High 134.13% on 11/21/25
  • IV Low 51.05% on 03/17/26
  • Expected Move (DTE 2) 1.89 (4.68%)
  • Put/Call Vol Ratio 0.22
  • Today's Volume 11
  • Volume Avg (30-Day) 45
  • Put/Call OI Ratio 0.31
  • Today's Open Interest 727
  • Open Int (30-Day) 980
  • Expected Range 38.40 to 42.18

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.01
  • Number of Estimates 3
  • High Estimate $0.05
  • Low Estimate $-0.06
  • Prior Year $0.01
  • Growth Rate Est. (year over year) -200.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.93 +22.35%
on 04/16/26
45.83 -12.09%
on 04/28/26
+6.82 (+20.38%)
since 04/13/26
3-Month
27.54 +46.30%
on 03/09/26
45.83 -12.09%
on 04/28/26
+7.06 (+21.25%)
since 02/13/26
52-Week
9.22 +337.22%
on 06/18/25
45.83 -12.09%
on 04/28/26
+29.41 (+270.31%)
since 05/13/25

Most Recent Stories

More News
TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues

MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today...

AXGN : 40.29 (-1.56%)
TELA : 0.9600 (-5.88%)
ANIK : 14.80 (+0.82%)
MDXG : 3.52 (-0.56%)
ELUT : 1.0500 (unch)
BVS : 10.40 (+2.56%)
Axogen, Inc. to Participate in the 2026 Bank of America Global Healthcare Conference

ALACHUA, Fla. and TAMPA, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral...

AXGN : 40.29 (-1.56%)
AxoGen: Q1 Earnings Snapshot

AxoGen: Q1 Earnings Snapshot

AXGN : 40.29 (-1.56%)
Axogen, Inc. Reports First Quarter 2026 Financial Results

ALACHUA, Fla. and TAMPA, Fla., April 28, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral...

AXGN : 40.29 (-1.56%)
Axogen's First BLA-Approved Quarter Could Validate the Revenue Model That Investors Bet On

Barchart Research What to Expect from AXGN Earnings AXGN Generated April 27, 2026 Current Price $39.39 EPS Estimate $$-0.28 Consensus Rating Strong Buy Average Move 16.78% Axogen's First BLA-Approved Quarter...

AXGN : 40.29 (-1.56%)
CVRx Announces Nomination of Michael Dale for Election to the Board of Directors

MINNEAPOLIS, April 20, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients...

AXGN : 40.29 (-1.56%)
CVRX : 5.22 (-0.95%)
Axogen, Inc. to Report First Quarter 2026 Financial Results on April 28, 2026

ALACHUA, Fla. and TAMPA, Fla., April 14, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral...

AXGN : 40.29 (-1.56%)
AxoGen: Q4 Earnings Snapshot

AxoGen: Q4 Earnings Snapshot

AXGN : 40.29 (-1.56%)
Axogen, Inc. Reports Fourth Quarter and Full-Year 2025 Financial Results

ALACHUA, Fla. and TAMPA, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral...

AXGN : 40.29 (-1.56%)
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences

ALACHUA, Fla. and TAMPA, Fla., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral...

AXGN : 40.29 (-1.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

AxoGen, Inc. engages in developing and marketing surgical solutions for peripheral nerves. The company's portfolio of products includes Avance Nerve Graft(R), AxoGuard Nerve Connector(R), AxoGuard Nerve Protector(R), Avive Soft Tissue Membrane(R), AcroVal Neurosensory & Motor Testing System(R) and AxoTouch...

See More

Key Turning Points

3rd Resistance Point 41.97
2nd Resistance Point 41.56
1st Resistance Point 40.92
Last Price 40.29
1st Support Level 39.87
2nd Support Level 39.46
3rd Support Level 38.82

See More

52-Week High 45.83
Last Price 40.29
Fibonacci 61.8% 31.84
Fibonacci 50% 27.52
Fibonacci 38.2% 23.20
52-Week Low 9.22

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.